Comparison of the efficacy of rechallenge with anti-PD-1 antibody monotherapy and BRAF/MEK inhibitor in advanced malignant melanoma: A single-center, retrospective cohort study
Anti-PD-1 antibody monotherapy (anti-PD-1) and BRAF/MEK inhibitors (BRAF/MEKi) are currently recognized as effective treatments for advanced-stage malignant melanoma (MM) and have become standard systemic treatments. However, many patients with MM still do not benefit from these therapies. In this s...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-04-01
|
| Series: | Dermatologica Sinica |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ds.DS-D-25-00005 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!